Psychiatr. praxi. 2015;16(1):6-10

Agomelatine in the treatment of depression under practice condition

MUDr.Sylva Racková, Ph.D.
Psychiatrická ambulance Třemošná, Psychiatrie s. r. o.

Agomelatine is a syntetic analogue of melatonin, agonist of melatonergic MT1, MT2 and antagonist of serotonergic 5-HT2C recceptors.

Agomelatine is antidepressant with unique pharmacological profile which it differs agomelatine from other antidepressant drugs like

SSRI and SNRI in efficacy, tolerability. The article focuses on its efficacy in depression treatment, its diference from SSRI and SNRI, and

its use in clinical practice, in patiens with somatic disorders.

Keywords: agomelatine, depression, SSRI, SNRI, somatic disorders

Published: April 20, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S. Agomelatine in the treatment of depression under practice condition. Psychiatr. praxi. 2015;16(1):6-10.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Švestka J. Agomelatin - melatoninové a noradrenalinové/dopaminové antidepresivum: syntéza starších a novějších poznatků. Farmakoterapie 2012; Suppl 3.
    2. Švestka J, Mohr P. Agomelatin, melatoninové a noradrenalinové/dopaminové antidepresivum-mechanismus účinku a klinické důsledky. Farmakoterapie 2012; 8(3): 256-263.
    3. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22(5): 283-291. Go to original source... Go to PubMed...
    4. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013; 203(3): 179-187. Go to original source... Go to PubMed...
    5. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011; 23: 1-12.
    6. Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013; 12: CD008851. Go to original source... Go to PubMed...
    7. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348: g1888. Go to original source... Go to PubMed...
    8. Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 1128-1137. Go to original source... Go to PubMed...
    9. Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kasper S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr 2013; 18: 163-170. Go to original source... Go to PubMed...
    10. Corruble E, de Bodinat C, Bela?di C, Goodwin GM. Agomelatine study group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-week randomized, controlled, double-blind trial. Int J Neuropsychopharmacol 2013; 16(10): 2219-2234. Go to original source... Go to PubMed...
    11. Quera-Salva MA, Hajak G, Philip P. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011; 26(5): 252-262. Go to original source... Go to PubMed...
    12. Laux G, Huttner NA. VIVALDI study group. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-na?ve patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract 2014; 18(2): 86-96. Go to original source... Go to PubMed...
    13. Ivanov SV, Samushiya MA. Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study. Neuropsychiatr Dis Treat. 2014; 10: 631-639. Go to original source... Go to PubMed...
    14. Serreti A, Cheisa A. Treatment-emergent sexual dysfunction related to antidepressants. A meta-analysis. J Clin Psychopharmacol 2009; 29: 259-266. Go to original source... Go to PubMed...
    15. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F, Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62(Suppl 3): 10-21.
    16. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011; 26(8): 537-542. Go to original source... Go to PubMed...
    17. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008; 28(3): 329-333. Go to original source... Go to PubMed...
    18. Žourková A, Holanová M, Novotná J. Sexuální funkce při léčbě depresivní poruchy agomelatinem. Psychiatr. praxi 2012; 13(1): 32-34.
    19. Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, Cornelio M, Martinotti G. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011; 25(1): 109-114. Go to PubMed...
    20. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012; 32(4): 487-491. Go to original source... Go to PubMed...
    21. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68(11): 1723-1732. Go to original source... Go to PubMed...
    22. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010; 71(5): 616-626. Go to original source... Go to PubMed...
    23. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010; 30(2): 135-144. Go to original source... Go to PubMed...
    24. EMA souhrn údajů o přípravku: SPC přípravku Valdoxan: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf.
    25. European Medicines Agency. Valdoxan (agomelatine). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d124, poslední revize 16.07.2014.
    26. Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014; 14(5): 539-551. Go to original source... Go to PubMed...
    27. Karaiskos D, Tzavellas E, Ilias I, Liappas I, Paparrigopoulos T. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. Int J Clin Pract. 2013; 67(3): 257-260. Go to original source... Go to PubMed...
    28. Tchekalarova J, Petkova Z, Pechlivanova. Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage and behavioral changes in a kainate model of temporal lobe epilepsy. Epilepsy Behav 2013; 27: 174-187. Go to original source... Go to PubMed...
    29. Aguiar CCT, Almeida AB, Araújo PVP, et al. Anticonvulsant effects of agomelatine in mice. Epilepsy Behav 2012; 24: 324-328. Go to original source... Go to PubMed...
    30. Vimala PV, Bhutada PS, Patel FR. Therapeutic potential of agomelatine in epilepsy and epileptic complications. Med Hypotheses. 2014; 82(1): 105-110. Go to original source... Go to PubMed...
    31. Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010; 341: c5222. Go to original source... Go to PubMed...
    32. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005; (3): CD002919. Go to original source...
    33. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for migraine management: agomelatine. Clin Neuropharmacol. 2013; 36(2): 65-67. Go to original source... Go to PubMed...
    34. Gahr M, Freudenmann RW, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013; 46: 214-220. Go to original source... Go to PubMed...
    35. Gahr M, Kratzer W, Fuchs M, Connemann BJ. Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity. Curr Drug Metab 2014 Sep 26. [Epub ahead of print]. Go to original source... Go to PubMed...
    36. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-Induced Liver Injury: A Review for Clinicians. Am J Psychiatry 2014; 171(4): 404-415. Go to original source... Go to PubMed...
    37. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006; 163(1): 101-108. Go to original source... Go to PubMed...
    38. Kasper S, Corruble E, Hale A. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol 2013; 28(1): 12-19. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.